Haptenation of sulfonamide reactive metabolites to cellular proteins

Molecular Pharmacology

Volumn 62, Issue 5, 2002, Pages 1011-1026

  Manchanda, Tarang ^a   Hess, David ^a   Dale, Lianna ^b   Ferguson, Stephen G ^b   Rieder, Michael J ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DRUG METABOLITE; HAPTEN; HYDROXYLAMINE; NITROSO DERIVATIVE; SULFAMETHOXAZOLE; SULFONAMIDE;

ANIMAL CELL; ARTICLE; CAVEOLA; CELL MEMBRANE; CELL SPECIFICITY; CELL SURFACE; CELL VIABILITY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; HUMAN; HUMAN CELL; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; IMMUNE SYSTEM; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING;

ANIMALS; ANTIOXIDANTS; ENDOCYTOSIS; HAPTENS; HUMANS; MICE; PROTEIN BINDING; PROTEINS; SULFAMETHOXAZOLE; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 0036840668     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.5.1011     Document Type: Article

References (38)

1. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD, Sweitzer BJ, and Leape LL (1997) The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. J Am Med Assoc 277:307-311.
2. Bolzacchini E, Meinardi S, Orlandi M, and Rindone B (1998) 'In vivo' models of hapten generation. Clin Exp Allerg 28(Suppl 4):83-86.
3. Carr A, Swanson C, Penny R, and Cooper DA (1993) Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystisis carinii pneumonia and AIDS. J Infect Dis 167:180-185.
4. Coleman JW (1998) Protein haptenation by drugs. Clin Exp Allerg 28(Suppl 4):79-82.
5. Coleman JW and Blanca M (1998) Mechanisms of drug allergy. Immunol Today 19:196-198.
6. Cribb AE, Miller M, Leeder JS, Hill J, and Spielberg SP (1991) Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab Disp 19:900-906.
7. Cribb AE, Nuss CE, Alberts DW, Lamphere DE, Grant DM, Grossman SJ, and Spielberg SP (1996) Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem Res Toxicol 9:500-507.
8. Cribb AE, Spielberg SP, and Griffin GP (1995) N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 23:406-414.
9. Daftarian MP, Filion LG, Cameron W, Conway B, Roy R, Tropper F, and Diaz-Mitona F (1995) Immune response to sulfamethoxazole in patients with AIDS. Clin Diagn Lab Immunol 2:199-204.
10. Ellis MK, Hill S, and Foster PM (1992) Reactions of nitrosonitrobenzenes with biological thiols: Identification and reactivity of glutathione-S-yl conjugates. Chem Biol Interact 82:151-163.
11. Gill HJ, Hough SJ, Naisbitt DJ, Maggs JL, Kitteringham NR, Pirmohammed M, and Park BK (1997) The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. J Pharmacol Exp Ther 282:795-801.
12. Goldstein RA and Patterson R (1984) Drug allergy: prevention, diagnosis and treatment. Ann Intern Med 100:302-303.
13. Hess DA and Rieder MJ (1997) The role of reactive drug metabolites in immune-mediated adverse drug reactions. Ann Pharmacother 31:1378-1387.
14. Kalish RS (1995) Antigen processing: The gateway to the immune response. J Am Acad Dermatol 34:640-652.
15. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 227:680-685.
16. Lefkovitz I, Kettman JR, and Frey JR (2000) Global analysis of gene expression in cells of the immune system. Electrophoresis 21:2688-2693.
17. Martin S and Weltzien HU (1994). T cell recognition of haptens, a molecular view. Int Arch Allergy Immunol 104:10-16.
18. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunzinker T, and Pichler WJ (1995) Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin and carbamazepine. J Immunol 155:462-472.
19. Meekins CV, Sullivan TJ, and Gruchalla RS (1994) Immunochemical analysis of sulfonamide drug allergy: Identification of sulfamethoxazole-substituted human serum proteins. J Allergy Clin Immunol 94(6 Pt 1):1017-1024.
20. Naisbitt DJ, Hough SJ, Gill HJ, Pirmohamed M, Kitteringham NR, and Park BK (1999) Cellular disposition of sulphamethoxazole and its metabolites: Implications for hypersensitivity. Br J Pharmacol 126:1393-1407.
21. Park BK, Coleman JW, and Kitteringham NR (1987) Drug disposition and drug hypersensitivity. Biochem Pharmacol 36:581-590.
22. Park BK and Kitteringham NR (1990) Drug-protein conjugation and its immunological consequences. Drug Metab Rev. 22:87-144.
23. Park BK, Pirmohamed M, and Kitteringham NR (1992). Idiosyncratic drug reactions: A mechanistic evaluation of risk factors. Br J Clin Pharmacol 34:377-395.
24. Park BK, Pirmohamed M, and Kitteringham NR (1995) The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 68:385-424.
25. Pirmohamed M, Madden S, and Park BK (1996) Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism. Clin Pharmacokinet 31:215-230.
26. Pirmohamed M and Park BK (1999) The adverse effects of drugs. Hosp Med 60:348-352.
27. Pohl LR, Satoh H, Christ DD, and Kenna JG (1988) The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol 28:367-387.
28. Rieder MJ (1993) Immunopharmacology and adverse drug reactions. J Clin Pharmacol 33:316-323.
29. Rieder MJ (1997) In vivo and in vitro testing for adverse drug reactions. Pediatr Clin North Am 44:93-111.
30. Rieder MJ (1994) Mechanisms of unpredictable adverse drug reactions. Drug Saf 11:196-212.
31. Rieder MJ, Krause R, and Bird IA (1995) Time-course toxicity of reactive sulfonamide metabolites. Toxicol 95:141-146.
32. Rieder MJ, Sisson E, Bird IA, and Almawi WY (1992) Suppression of T-lymphocyte proliferation by sulphonamide hydroxylamines. Int J Immunopharmacol 14:1175-1180.
33. Rieder MJ, Uetrecht J, Shear NH, and Spielberg SP (1988) Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J Pharmacol Exp Ther 244:724-728.
34. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, and Spielberg SP (1989) Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med 110:286-289.
35. Shear NH, Spielberg SP, Grant DM, Tang BK, and Kalow W (1986) Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 1986 Aug;105:179-184.
36. Spielberg SP, Gordon GB, Blake DA, Mellits ED, and Bross DS (1981) Anticonvulsant toxicity in vitro: Possible role of arene oxides. J Pharmacol Exp Ther 217:386-389.
37. Weinshilboum RM (1987) The therapeutic revolution. Clin Pharmacol Ther 42:481-484.
38. Weltzien HU, Moulon C, Martin S, Padovan E, Hartmann U, and Kohler J (1996) T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Toxicology 107:141-151.